DelveInsight’s, “Parkinson’s Disease Pipeline Insight 2024” report provides comprehensive insights about 130+ companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Parkinson’s Disease Research. Learn more about our innovative pipeline today! @ Parkinson’s Disease Pipeline Outlook
Key Takeaways from the Parkinson’s Disease Pipeline Report
- In November 2024:- Denali Therapeutics Inc.- This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson’s Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
- In November 2024:- iRegene Therapeutics Co., Ltd.- This is a multi-center, single arm, and open label trial. The NouvNeu001 will be transplanted into bilateral putamen/striatum using stereotactic neurosurgery. Subjects will take immunosuppressants to prevent potential immune rejection for 24 to 36 weeks. This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson’s disease.
- In November 2024:- Cerevel Therapeutics Inc- The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson’s Disease.
- DelveInsight’s Parkinson’s Disease pipeline report depicts a robust space with 130+ active players working to develop 150+ pipeline therapies for Parkinson’s Disease treatment.
- The leading Parkinson’s Disease Companies such as Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Prevail Therapeutics, Luye Pharma Group Ltd, FAScinate Therapeutics Inc., Neurocrine Biosciences, Sangamo Therapeutics, AstraZeneca, Hoffmann-La Roche, Brain Neurotherapy Bio, Inc, Annovis Bio Inc, Anavex Life Sciences Corp, Alexza Pharmaceuticals, Inc., Pharma Two B Ltd., MeiraGTx, LLC, BioVie Inc., Takeda Pharmaceuticals, and others.
- Promising Parkinson’s Disease Therapies such as Apomorphine Infusion, CVN424 150 mg, MT101-5, BIA 28-6156 10 mg, RO7046015, ND0612, and others.
Stay informed about the cutting-edge advancements in Parkinson’s Disease treatments. Download for updates and be a part of the revolution in care @ Parkinson’s Disease Clinical Trials Assessment
Parkinson’s disease Emerging Drugs Profile
- Buntanetap: Annovis Bio
Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients. Currently, the drug is in Phase III trial for the treatment of Parkinson’s disease.
- Tavapadon: Cerevel Therapeutics
Tavapadon is the first and only selective D1/D5 receptor partial agonist in development for Parkinson’s disease and is currently being studied as a once-daily medicine for use as both a monotherapy and as an adjunctive therapy to LD. Tavapadon is designed to selectively and optimally activate D1/D5 receptors to potentially provide the right balance of motor control, safety and tolerability for patients. By selectively activating D1/D5 dopamine receptors along the nigrostriatal pathway, tavapadon has the potential to offer the right balance of dopamine signaling to improve motor control while avoiding D2/D3 overstimulation, which is believed to underlie many of the side effects of current dopamine agonists. Additionally, as a partial agonist with a 24-hour half-life enabling once-daily dosing, tavapadon may avoid hyper activation of the dopamine receptors, which can lead to troublesome dyskinesias. Currently, the drug is in Phase III trial for the treatment of Parkinson’s disease.
- Prasinezumab: Roche
Prasinezumab (RG7935) is a monoclonal antibody targeting alpha-synuclein, a protein that may misfold and be involved in the pathogenesis of Parkinson’s disease. It has been tested in preclinical models of synuclein-related disease and has shown a reduction of neurodegeneration. Currently, the drug is in Phase II trial for the treatment of Parkinson’s disease.
- Risvodetinib: Inhibikase Therapeutics, Inc
Risvodetinib (IkT-148009), is a potent, selective small-molecule designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. Risvodetinib (IkT-148009) is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms. Currently, the drug is in Phase II trial for the treatment of Parkinson’s disease.
- GT 02287: Gain Therapeutics
GT-02287, is an allosteric regulator of GCase and is in development for the treatment of PD, with GBA1-PD as the lead indication. The orally administered, brain-penetrant small molecule restores the function of GCase. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced cellular stress in the endoplasmic reticulum, improved lysosomal function and mitochondrial function, reduced toxic glycosphingolipids, aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function. Currently, the drug is in Phase I trial for the treatment of Parkinson’s disease.
- NNI 362: Neuronascent
NNI-362 is Neuronascent’s patented oral therapeutic aimed at reversing age-related disorders by producing new neurons to replace those lost in chronic neurodegenerative disorders and aging. NNI-362 has a unique mechanism of action (MOA) that provides safety and selectivity specifically for neuron regeneration, and was discovered through Neuronascent’s proprietary phenotypic screening program using human neural progenitors. This MOA takes advantage of the neural progenitors already in the aged brain to promote new neurons and protect them from degeneration in chronic diseases of the aged, specifically Alzheimer’s disease. New neuron regeneration from neural progenitors is a physiologic process in the brain, yet with aging and neurodegenerative disease there begins a pathological insufficiency in generating new neurons that survive to functionality. Thus, NNI-362 is aimed at reversing age-related neuron loss and restoring cognitive function in AD patients, and should also be useful for other disorders of the elderly, including Parkinson’s disease and age-related hearing loss. Currently, the drug is in preclinical stage for the treatment of Parkinson’s disease.
Learn more about Parkinson’s Disease Drugs opportunities in our groundbreaking Parkinson’s Disease Research and development projects @ Parkinson’s Disease Unmet Needs
Parkinson’s Disease Companies
Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Prevail Therapeutics, Luye Pharma Group Ltd, FAScinate Therapeutics Inc., Neurocrine Biosciences, Sangamo Therapeutics, AstraZeneca, Hoffmann-La Roche, Brain Neurotherapy Bio, Inc, Annovis Bio Inc, Anavex Life Sciences Corp, Alexza Pharmaceuticals, Inc., Pharma Two B Ltd., MeiraGTx, LLC, BioVie Inc., Takeda Pharmaceuticals, and others.
Parkinson’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Parkinson’s Disease Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Discover the latest advancements in Parkinson’s Disease treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Parkinson’s Disease Market Drivers and Barriers, and Future Perspectives
Scope of the Parkinson’s Disease Pipeline Report
- Coverage- Global
- Parkinson’s Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Prevail Therapeutics, Luye Pharma Group Ltd, FAScinate Therapeutics Inc., Neurocrine Biosciences, Sangamo Therapeutics, AstraZeneca, Hoffmann-La Roche, Brain Neurotherapy Bio, Inc, Annovis Bio Inc, Anavex Life Sciences Corp, Alexza Pharmaceuticals, Inc., Pharma Two B Ltd., MeiraGTx, LLC, BioVie Inc., Takeda Pharmaceuticals
- Parkinson’s Disease Therapies- Apomorphine Infusion, CVN424 150 mg, MT101-5, BIA 28-6156 10 mg, RO7046015, ND0612, and others.
- Parkinson’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Parkinson’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Parkinson’s Disease Pipeline on our website @ Parkinson’s Disease Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Parkinson’s disease : Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Parkinson’s Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Buntanetap: Annovis Bio
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Risvodetinib: Inhibikase Therapeutics, Inc
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- GT 02287: Gain Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- NNI 362: Neuronascent
- Drug profiles in the detailed report…..
- Inactive Products
- Parkinson’s disease Key Companies
- Parkinson’s disease Key Products
- Parkinson’s disease – Unmet Needs
- Parkinson’s disease – Market Drivers and Barriers
- Parkinson’s disease – Future Perspectives and Conclusion
- Parkinson’s disease Analyst Views
- Parkinson’s disease Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/